KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $32.60.

A number of equities research analysts have issued reports on KALV shares. HC Wainwright upped their price objective on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Needham & Company LLC upped their price objective on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Wall Street Zen downgraded KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus upped their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, March 26th.

Insider Activity

In other news, insider Paul K. Audhya sold 5,354 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $83,361.78. Following the transaction, the insider owned 138,983 shares of the company’s stock, valued at approximately $2,163,965.31. This represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Nicole Sweeny sold 3,975 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $61,890.75. Following the transaction, the insider directly owned 47,003 shares in the company, valued at approximately $731,836.71. This represents a 7.80% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 248,009 shares of company stock valued at $4,213,467. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets grew its stake in shares of KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $55,000. Wolverine Asset Management LLC bought a new position in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $57,000. Truvestments Capital LLC grew its stake in KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in KalVista Pharmaceuticals in the third quarter worth approximately $63,000.

KalVista Pharmaceuticals Trading Down 0.3%

Shares of KALV stock opened at $20.12 on Wednesday. KalVista Pharmaceuticals has a 1 year low of $9.23 and a 1 year high of $21.31. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The stock’s 50 day simple moving average is $16.65 and its two-hundred day simple moving average is $14.75. The company has a market cap of $1.03 billion, a PE ratio of -5.09 and a beta of -0.40.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.